PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Gender-related efficacy of pulmonary surfactant in infants with respiratory distress syndrome: A STROBE compliant study.

Abstract Whether gender influences the efficacy of exogenous pulmonary surfactant (PS) for replacement therapy in newborns with respiratory distress syndrome (RDS) has not been well studied yet.Retrospective cohort study design. Data on PS therapy including blood gas, oxygenation function parameters, and therapy results were collected and analyzed from 370 infants diagnosed with RDS in 20 hospitals of the Northwest China Neonatal Collaboration from January 2011 to December 2011.Female infants were more sensitive to PS treatment than males. In multivariate analysis, when adjusted for other variables, an increased initial dose of surfactant significantly reduced mortality risk (OR = 0.98, 95%CI [0.96, 0.99], P = .002). An interaction between gender and initial dose of PS was observed. In male infants, an increased initial dose of surfactant was correlated with reduced mortality risk (OR = 0.97, 95%CI [0.96, 0.99], P = 0.005), while in female infants, we failed to found a relationship between the initial dose of surfactant and the risk of mortality (OR = 0.99, 95%CI [0.96, 1.02], P = .543). Moreover, the effect of surfactant replacement therapy was better for female infants than male infants at initial PS doses <130 mg/kg.Gender influences the efficacy of PS treatment. An increased initial dose of PS should be used in RDS therapy for male infants.
PMID
Related Publications

Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome.

The clinical comparative study of preterm respiratory distress syndrome and transient tachypnea of newborn.

Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome.

Evaluation of the effects of surfactant replacement therapy in neonatal respiratory distress syndrome.

Epidemiological survey of neonatal respiratory distress syndrome in part of northwest regions in China.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29702992
OWN - NLM
STAT- MEDLINE
DCOM- 20180514
LR  - 20180516
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 17
DP  - 2018 Apr
TI  - Gender-related efficacy of pulmonary surfactant in infants with respiratory
      distress syndrome: A STROBE compliant study.
PG  - e0425
LID - 10.1097/MD.0000000000010425 [doi]
AB  - Whether gender influences the efficacy of exogenous pulmonary surfactant (PS) for
      replacement therapy in newborns with respiratory distress syndrome (RDS) has not 
      been well studied yet.Retrospective cohort study design. Data on PS therapy
      including blood gas, oxygenation function parameters, and therapy results were
      collected and analyzed from 370 infants diagnosed with RDS in 20 hospitals of the
      Northwest China Neonatal Collaboration from January 2011 to December 2011.Female 
      infants were more sensitive to PS treatment than males. In multivariate analysis,
      when adjusted for other variables, an increased initial dose of surfactant
      significantly reduced mortality risk (OR = 0.98, 95%CI [0.96, 0.99], P = .002).
      An interaction between gender and initial dose of PS was observed. In male
      infants, an increased initial dose of surfactant was correlated with reduced
      mortality risk (OR = 0.97, 95%CI [0.96, 0.99], P = 0.005), while in female
      infants, we failed to found a relationship between the initial dose of surfactant
      and the risk of mortality (OR = 0.99, 95%CI [0.96, 1.02], P = .543). Moreover,
      the effect of surfactant replacement therapy was better for female infants than
      male infants at initial PS doses &lt;130 mg/kg.Gender influences the efficacy of PS 
      treatment. An increased initial dose of PS should be used in RDS therapy for male
      infants.
FAU - Chen, Chen
AU  - Chen C
AD  - Department of Neonatology, First Affiliated Hospital of Xi'an Jiaotong
      University.
AD  - Department of Neonatology, Xi'an Children's Hospital, Xi'an, China.
FAU - Tian, Tian
AU  - Tian T
AD  - Department of Neonatology, First Affiliated Hospital of Xi'an Jiaotong
      University.
FAU - Liu, Li
AU  - Liu L
AD  - Department of Neonatology, First Affiliated Hospital of Xi'an Jiaotong
      University.
FAU - Zhang, Juan
AU  - Zhang J
AD  - Department of Neonatology, First Affiliated Hospital of Xi'an Jiaotong
      University.
FAU - Fu, Huiling
AU  - Fu H
AD  - Department of Neonatology, First Affiliated Hospital of Xi'an Jiaotong
      University.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Pulmonary Surfactants)
SB  - AIM
SB  - IM
MH  - Apgar Score
MH  - Birth Weight
MH  - Blood Gas Analysis
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Gestational Age
MH  - Humans
MH  - Infant, Newborn
MH  - Male
MH  - Pulmonary Surfactants/*therapeutic use
MH  - Respiratory Distress Syndrome, Newborn/*drug therapy/mortality
MH  - Retrospective Studies
MH  - Sex Factors
MH  - Socioeconomic Factors
PMC - PMC5944534
EDAT- 2018/04/29 06:00
MHDA- 2018/05/15 06:00
CRDT- 2018/04/29 06:00
PHST- 2018/04/29 06:00 [entrez]
PHST- 2018/04/29 06:00 [pubmed]
PHST- 2018/05/15 06:00 [medline]
AID - 10.1097/MD.0000000000010425 [doi]
AID - 00005792-201804270-00024 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Apr;97(17):e0425. doi: 10.1097/MD.0000000000010425.